Seagen Inc. (SGEN) CEO Clay Siegall on Q1 2021 Results - Earnings Call Transcript

May 01, 2021 8:29 AM ETSeagen Inc. (SGEN) StockSGEN
SA Transcripts
153.96K Followers

Seagen Inc. (SGEN) Q1 2021 Earnings Conference Call April 29, 2021 4:30 PM ET

Company Participants

Peggy Pinkston - Senior Vice President of Investor Relations
Clay Siegall - President and Chief Executive Officer
Chip Romp - Executive Vice President, Commercial U.S
Todd Simpson - Chief Financial Officer
Roger Dansey - Chief Medical Officer

Conference Call Participants

Greg Harrison - Bank of America
Connor Meehan - Morgan Stanley
Salveen Richter - Goldman Sachs
Turner Kufe - JPMorgan
Michael Schmidt - Guggenheim
Andrew Berens - SVB Leerink
Kennen MacKay - RBC Capital Markets
Xiaozhou Fan - Barclays
Ellen Sands - Stifel
Andy Hsieh - William Blair
Jay Olson - Oppenheimer
Ren Benjamin - JMP Securities
Shanshan Xu - Berenberg
Brad Canino - Credit Suisse

Operator

Good day and welcome to Seagen's First Quarter 2021 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Peggy Pinkston, Senior Vice President of Investor Relations. Please go ahead.

Peggy Pinkston

Thank you, operator, and good afternoon, everyone. I'd like to welcome all of you to Seagen's First Quarter 2021 Financial Results Conference Call. This afternoon, we issued a press release with our results. The press release and supporting slides are available on our website in the Investors section, Events and Presentations page.

Speakers on today's call will be Clay Siegall, President and Chief Executive Officer; Chip Romp, Executive Vice President, Commercial U.S.; Todd Simpson, Chief Financial Officer; and Roger Dansey, Chief Medical Officer. Following our prepared remarks, we'll open the line for questions. We aim to keep this call to 1 hour. [Operator Instructions]

Today's conference call will include forward-looking statements regarding future or anticipated events and results, including the company's 2021 financial outlook; anticipated product sales, revenues, costs and expenses; and potential clinical and regulatory milestones, including

Recommended For You

More on SGEN